NCT02452151Unknown4 期
Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission.
Onze Lieve Vrouwe Gasthuis0 个研究点目标入组 300 人开始时间: 2015年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 300
- 主要终点
- Duration of clinical remission
研究概览
简要总结
The objective of this study is to compare the efficacy of Infliximab-Biosimilar to Infliximab-Innovator and to demonstrate its noninferiority, in patients with ulcerative colitis or Crohn's disease in remission under treatment with infliximab up to 3 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients, male or female, aged above 18 years at time of enrolment will be selected from hospital databases based on appointments for Infliximab infusion as treatment for IBD. Patients are eligible for inclusion if they have an established diagnosis of ulcerative colitis or Crohn's disease, are in clinical remission and are medically treated with Infliximab for at least 12 weeks prior to inclusion.
排除标准
- •Patient has an allergy or hypersensitivity to one of the components of infliximab and/or immunoglobulin products, except hypersensitivity reactions which have a positive response to hydrocortisone and thereby are under control.
- •Patient has a current diagnosis with hepatitis B, hepatitis C or an infection with human immunodeficiency virus (HIV)-1 or
- •Patients with a past history of chronic hepatitis B or hepatitis C will not be excluded.
- •Patient has a history of tuberculosis (TB) or a current diagnosis of TB or other severe or chronic infection such as abscess, opportunistic infection or invasive fungal infection. Patients with a past history of a severe or chronic infection will not be excluded.
- •Patient has had recent exposure to persons with active TB. In that case screening for latent TB (defined as a positive result for interferon-γ release assay (IGRA) with a negative examination of chest X-ray) will be performed. If there is sufficient documentation of prophylaxis or complete resolution following TB-treatment based on hospital-specific guidelines the patient can be enrolled. If the result of the IGRA is indeterminate at screening, 1 retest will be done. If the repeated IGRA result is indeterminate again, the patient will be excluded. Patients with a positive IGRA result and a negative examination of chest X-ray who has received at least the first 30 days of TB-therapy can be enrolled.
- •Patient who is taking any of the following concomitant medications or treatment:
- •Corticosteroids (prednisone, prednisolone or budosenide).
- •Live or live-attenuated vaccine within 8 weeks of randomization.
- •Any other biological treatments than infliximab.
- •Subtotal and total colectomy prior to randomization.
- •Any planned abdominal surgery for IBD at the time of randomization and/or during the study period.
- •Patient has one or more of the following medical conditions:
- •Active entero-vesical, entero-retroperitoneal, entero-cutaneous and entero-vaginal fistula for within 6 months prior to screening. Entero-enteral fistulae without clinical significant symptoms upon investigator's opinion and anal fistulae without draining problems are allowed.
- •Current short bowel syndrome.
- •History of any malignancy within the 5 years prior to randomization except cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma or completely excised and cured squamous carcinoma of the uterine cervix.
- •History of lymphoma or lymphproliferative disease or bone marrow hyperplasia.
- •New York Heart Association (NYHA) class III or IV heart failure.
- •History of organ transplantation, including corneal graft/transplantation.
- •Patient has had treatment with any other investigational device or medical product within 4 weeks of randomization or 5 half-lives, whichever is longer.
- •Female patient who is currently pregnant, breastfeeding or planning to become pregnant or breastfeed within 6 months of the last dose of study drug.
研究组 & 干预措施
Infliximab-biosimilar
Experimental
Infliximab-Biosimilar (Inflectra) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
干预措施: Infliximab-Biosimilar (Drug)
Infliximab-Innovator
Active Comparator
Infliximab-Innovator (Remicade) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
干预措施: Infliximab-Innovator (Drug)
结局指标
主要结局
Duration of clinical remission
时间窗: 3 months
Efficacy of Infliximab-Biosimilar and Infliximab will be assessed by evaluation of the the duration of clinical remission for each diagnosis seperately.
Relapse rate
时间窗: 3 months
Efficacy of Infliximab-Biosimilar and Infliximab will be assessed by evaluation of the relapse rate for each diagnosis seperately.
次要结局
未报告次要终点
研究者
J.M. Jansen, MD
J.M. Jansen, MD
Onze Lieve Vrouwe Gasthuis
相似试验
已完成
不适用
The effect of switching treatment from innovator infliximab to infliximab biosimilar on efficacy, safety and immunogenicity in patients with rheumatoid arthritis, spondyloarthritis or psoriatic arthritis in daily clinical careBiosimilar, Infliximab, Inflectra, RemsimaNL-OMON24401Participating hospitals are:Sint Maartenskliniek NijmegenMaartenskliniek WoerdenRadboud University Medical Centre NijmegenRijnstate Arnhem200
已完成
3 期
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)Rheumatoid ArthritisNCT02990806Nichi-Iko Pharmaceutical Co., Ltd.683
已完成
早期 1 期
Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis SuppurativaHidradenitis SuppurativaNCT05663268Services Institute of Medical Sciences, Pakistan37
进行中（未招募）
1 期
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical TrialModerate to Severe Chronic Plaque PsoriasisNCT06591273Services Institute of Medical Sciences, Pakistan104
已完成
4 期
SIMILAR Trial: Santeon InflixMab biosimILAr Research A randomized, controlled, double blind, phase 4 noninferiority trial to assess efficacy of Infliximab-biosimilar (Inflectra) compared to Infliximab-innovator (Remicade) in patients with inflammatory bowel disease in remissioInflammatory Bowel disease: ulcerative colitis and Crohn's disease1001794310003816NL-OMON43635Santeon182